RU2005112752A - Производные пиридина в качестве модуляторов рецептора сb2 - Google Patents
Производные пиридина в качестве модуляторов рецептора сb2 Download PDFInfo
- Publication number
- RU2005112752A RU2005112752A RU2005112752/04A RU2005112752A RU2005112752A RU 2005112752 A RU2005112752 A RU 2005112752A RU 2005112752/04 A RU2005112752/04 A RU 2005112752/04A RU 2005112752 A RU2005112752 A RU 2005112752A RU 2005112752 A RU2005112752 A RU 2005112752A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- hydrogen
- substituted
- halogen
- unsubstituted
- Prior art date
Links
- 0 CC(c(c(*)c1)c(C)nc1N(*)*)=O Chemical compound CC(c(c(*)c1)c(C)nc1N(*)*)=O 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (16)
1. Соединение формулы (I)
в которой Y означает фенил, незамещенный или замещенный одним, двумя или тремя заместителями;
R1 выбран из водорода, C1-6алкила, С3-6циклоалкила или замещенного галогеном C1-6алкила;
R2 означает (CH2)mR3, где т означает 0 или 1;
или R1 или R2 вместе с атомом азота, с которым они соединены, образуют возможно замещенный 4-8-членный неароматический гетероцикл;
R3 означает 4-8-членную неароматическую гетероциклическую группу, С3-8циклоалкильную группу, линейный или разветвленный C1-10алкил, С2-10алкенил, С3-8циклоалкенил, С2-10алкинил или С3-8ациклоалкинил, каждый из которых может быть замещен или незамещен, или означает R5;
R4 выбран из водорода, C1-6алкила, С3-6циклоалкила или замещенного галогеном C1-6алкила, СОСН3 или SO2Ме;
R5 означает группу
в которой р означает 0, 1 или 2, и Х означает CH2, О или S;
R6 означает замещенный или незамещенный (С1-6)алкил или хлор и R10 означает водород, или R10 означает замещенный или незамещенный (С1-6)алкил или хлор и R6 означает водород;
R7 означает ОН, C1-6алкокси, NR8aR8b, NHCOR9, NHSO2R9 или SOqR9;
R8a означает Н или С1-6алкил;
R8b означает Н или C1-6алкил;
R9 означает C1-6алкил;
q означает 0, 1 или 2;
или его фармацевтически приемлемое производное.
2. Соединение по п.1 формулы (Ia)
в которой R1 выбран из водорода, C1-6алкила, С3-6циклоалкила или замещенного галогеном C1-6алкила;
R2 означает (CH)mR3, где m означает 0 или 1;
или R1 и R2 вместе с атомом азота, с которым они соединены, образуют гетероциклический не ароматический цикл, выбранный из азетидинила, пирролидинила, морфолинила, пиперазинила, пиперйдинила, тетрагидропиридинила, азапина, оксапина, азациклооктанила, азаоксациклооктанила и азатиациклооктанила, причем любой из них может быть незамещен или замещен 1, 2 или 3 заместителями, выбранными из C1-6алкила, C1-6алкоксила, гидроксила, цианогруппы, галогена, сульфонила, метилсульфонила, группы NR8aR8b, СН2фенила, NHCOCH3, (=O), CONHCH3 и NHSO2СН3;
R3 означает 2- или 3-азетидинил, оксетанил, тиоксетанил, тиоксетанил-s-оксид, тиоксетанил-s,s-диоксид, диоксаланил, пирролидинил, тетрагидрофуранил, тетрагидротиофенил, тетрагидротиофенил-s,s-диоксид, морфолинил, пиперидинил, пиперазинил, тетрагидропиранил, тетрагидротиопиранил, тиоморфолинил, тиоморфолинил-s,s-диоксид, тетрагидропиридинил, диоксанил, тетрагидротиопиран-1,1-диоксид, азапин, оксапин, азациклооктанил, азаоксациклооктанил, азатиациклооктанил, оксациклооктанил, тиациклооктанил, С3-8циклоалкильная группа, линейный или разветвленный C1-10алкил, С2-10алкенил, С3-8циклоалкенил, С2-10алкинил или С3-8циклоалкинил, или R5; причем любой из них может быть незамещен или замещен 1, 2 или 3 заместителями, выбранными из C1-6алкила, C1-6алкоксила, гидроксила, циано, галогена, сульфонила, метилсульфонила, группы NR8aR8b, СН2фенила, NHCOCH3, (=O), CONHCH3 и NHSO2СН3;
R4 выбран из водорода, C1-6алкила, С3-6циклоалкила или замещенного галогеном C1-6алкила, СОСН3 или SO2Ме;
R5 означает группу
в которой р означает 0, 1 или 2 и Х означает СН2, О или S;
R6 означает замещенный или незамещенный (С1-6)алкил или хлор и R10 означает водород, или R10 означает замещенный или незамещенный (C1-6)алкил или хлор и R6 означает водород;
R7 означает ОН, C1-6алкокси, NR8aR8b, NHCOR9, NHSO2R9 или SOqR9;
R8b значает Н или C1-6алкил;
R8b означает Н или C1-6алкил;
R9 означает C1-6алкил;
R11 означает C1-6алкил, замещенный галогеном C1-6алкил, C1-6алкокси, гидроксил, цианогруппу, галоген, C1-6алкилсульфонильную группу, -CONH2, NHCOCH3, -СООН, замещенный галогеном C1-6алкоксил, группу SO2NR8aR8b или C1-6алкинил;
q означает 0, 1 или 2;
d означает 0, 1, 2 или 3;
или его фармацевтически приемлемое производное.
3. Соединение по п.1 или 2, в котором R1 означает водород.
4. Соединение по п.1 или 2, в котором R4 означает C1-6алкил или водород.
5. Соединение по п.1 или 2, в котором R1 означает водород и R4 означает C1-6алкил или водород.
6. Соединение по п.1 или 2, в котором R6 означает трет-бутил, изопропил или CF3.
7. Соединение по п.1 или 2, в котором R1 означает водород и R6 означает трет-бутил, изопропил или CF3.
8. Соединение по п.1 или 2, в котором R4 означает C1-6алкил или водород и R6 означает трет-бутил, изопропил или CF3.
9. Соединение по п.1 или 2, в котором R1 означает водород и R4 означает C1-6алкил или водород и R6 означает трет-бутил, изопропил или CF3.
10. Фармацевтическая композиция, содержащая соединение по п.1 или 2, или его фармацевтически приемлемое производное.
11. Фармацевтическая композиция по п.10, в котором соединением формулы I является соединение, где R1 означает водород и R4 означает C1-6алкил или водород и R6 означает трет-бутил, изопропил или CF3 или его фармацевтически приемлемое производное.
12. Фармацевтическая композиция по п.10, которая дополнительно включает фармацевтический носитель или разбавитель.
13. Способ лечения состояний, опосредованных активностью рецептора каннабиноида 2, включающий введение млекопитающему терапевтически эффективного количества соединения формулы (I) по любому из п.п.1-2, или его фармацевтически приемлемого производного.
14. Способ по п.13, в котором соединением формулы I является соединение, где R1 означает водород и R4 означает C1-6алкил или водород и R6 означает трет-бутил, изопропил или CF3 или его фармацевтически приемлемое производное.
15. Способ по п.13, в котором состоянием является иммунное нарушение, воспалительное заболевание, боль, ревматоидный артрит, рассеянный склероз, остеоартрит или остеопороз.
16. Способ по п.14, в котором состоянием является иммунное нарушение, воспалительное заболевание, боль, ревматоидный артрит, рассеянный склероз, остеоартрит или остеопороз.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0222493.9A GB0222493D0 (en) | 2002-09-27 | 2002-09-27 | Compounds |
GB0222493.9 | 2002-09-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2005112752A true RU2005112752A (ru) | 2006-01-20 |
Family
ID=9944904
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2005112752/04A RU2005112752A (ru) | 2002-09-27 | 2003-09-25 | Производные пиридина в качестве модуляторов рецептора сb2 |
Country Status (23)
Country | Link |
---|---|
US (1) | US20060240048A1 (ru) |
EP (1) | EP1565442B1 (ru) |
JP (1) | JP2006503845A (ru) |
KR (1) | KR20050071514A (ru) |
CN (1) | CN1703402A (ru) |
AR (1) | AR041395A1 (ru) |
AT (1) | ATE378317T1 (ru) |
AU (1) | AU2003268907A1 (ru) |
BR (1) | BR0314635A (ru) |
CA (1) | CA2500231A1 (ru) |
DE (1) | DE60317555T2 (ru) |
ES (1) | ES2294313T3 (ru) |
GB (1) | GB0222493D0 (ru) |
IS (1) | IS7809A (ru) |
MA (1) | MA27448A1 (ru) |
MX (1) | MXPA05003263A (ru) |
NO (1) | NO20052028L (ru) |
NZ (1) | NZ538943A (ru) |
PL (1) | PL375990A1 (ru) |
RU (1) | RU2005112752A (ru) |
TW (1) | TW200413321A (ru) |
WO (1) | WO2004029026A1 (ru) |
ZA (1) | ZA200502084B (ru) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2567390C2 (ru) * | 2009-08-24 | 2015-11-10 | Ньюралстем, Инк. | Получение нейростимулирующего пиперазина |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1492784A4 (en) | 2002-03-28 | 2006-03-29 | Merck & Co Inc | SUBSTITUTED 2,3-DIPHENYLPYRIDINES |
UY27939A1 (es) | 2002-08-21 | 2004-03-31 | Glaxo Group Ltd | Compuestos |
AR043633A1 (es) | 2003-03-20 | 2005-08-03 | Schering Corp | Ligandos de receptores de canabinoides |
GB0402357D0 (en) * | 2004-02-03 | 2004-03-10 | Glaxo Group Ltd | Novel compounds |
GB0402356D0 (en) * | 2004-02-03 | 2004-03-10 | Glaxo Group Ltd | Novel compounds |
GB0402355D0 (en) * | 2004-02-03 | 2004-03-10 | Glaxo Group Ltd | Novel compounds |
SE0401343D0 (sv) * | 2004-05-25 | 2004-05-25 | Astrazeneca Ab | Therapeutic compounds: Pyridine N oxide as scaffold |
SE0401345D0 (sv) * | 2004-05-25 | 2004-05-25 | Astrazeneca Ab | Therapeutic compounds: Pyridine as scaffold |
SE0401342D0 (sv) * | 2004-05-25 | 2004-05-25 | Astrazeneca Ab | Therapeutic compounds |
DE602005010698D1 (de) | 2004-06-09 | 2008-12-11 | Glaxo Group Ltd | Pyrrolopyridinderivate |
AR055601A1 (es) * | 2005-08-09 | 2007-08-29 | Glaxo Group Ltd | Compuestos derivados de imidazopiridina como ligandos de receptores canabinoides |
GB0519760D0 (en) * | 2005-09-28 | 2005-11-09 | Glaxo Group Ltd | Novel compounds |
WO2007118041A1 (en) * | 2006-04-07 | 2007-10-18 | Boehringer Ingelheim International Gmbh | Compounds which modulate the cb2 receptor |
MX2009003316A (es) * | 2006-10-04 | 2009-04-09 | Hoffmann La Roche | Derivados de pirazina-2-carboxamida como moduladores receptores de cb2. |
WO2008063625A2 (en) * | 2006-11-20 | 2008-05-29 | Adolor Corporation | Pyridine compounds and methods of their use |
AU2007347456B2 (en) * | 2007-02-22 | 2011-10-06 | Hemerus Medical, Llc | A high capacity biological fluid filtration apparatus |
CA2747801A1 (en) * | 2009-01-22 | 2010-07-29 | Raqualia Pharma Inc. | N-substituted saturated heterocyclic sulfone compounds with cb2 receptor agonistic activity |
EP2415765A4 (en) | 2009-03-30 | 2012-08-15 | Astellas Pharma Inc | PYRIMIDINE COMPOUND |
US9321727B2 (en) | 2011-06-10 | 2016-04-26 | Hoffmann-La Roche Inc. | Pyridine derivatives as agonists of the CB2 receptor |
JP2013048962A (ja) * | 2012-12-12 | 2013-03-14 | Hemerus Medical Llc | 大容量の体液濾過装置 |
WO2018055640A1 (en) * | 2016-09-22 | 2018-03-29 | Srf Limited | Process for the preparation of haloalkyl derivatives of nicotinic acid |
CN112262132A (zh) * | 2018-06-27 | 2021-01-22 | 豪夫迈·罗氏有限公司 | 作为大麻素受体2的抑制剂的新型吡啶和吡嗪化合物 |
WO2020025574A1 (en) | 2018-08-03 | 2020-02-06 | Bayer Aktiengesellschaft | Process for the preparation of 6-(haloalkyl)-2-halo-5-acylpyridines and intermediates for this process |
EP3666759A1 (en) | 2018-12-10 | 2020-06-17 | Bayer Aktiengesellschaft | Preparation of 6-halo-2-(haloalkyl)-3-acylpyridines and intermediates therefor |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5112820A (en) * | 1990-03-05 | 1992-05-12 | Sterling Drug Inc. | Anti-glaucoma compositions containing 2- and 3-aminomethyl-6-arylcarbonyl- or 6-phenylthio-2,3-dihydropyrrolo-(1,2,3-de)-1,4-benzoxazines and method of use thereof |
FR2742148B1 (fr) * | 1995-12-08 | 1999-10-22 | Sanofi Sa | Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant |
US6022884A (en) * | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
US7507767B2 (en) * | 2001-02-08 | 2009-03-24 | Schering Corporation | Cannabinoid receptor ligands |
-
2002
- 2002-09-27 GB GBGB0222493.9A patent/GB0222493D0/en not_active Ceased
-
2003
- 2003-09-25 TW TW092126422A patent/TW200413321A/zh unknown
- 2003-09-25 KR KR1020057005234A patent/KR20050071514A/ko not_active Application Discontinuation
- 2003-09-25 PL PL03375990A patent/PL375990A1/xx not_active Application Discontinuation
- 2003-09-25 JP JP2004539056A patent/JP2006503845A/ja not_active Withdrawn
- 2003-09-25 BR BR0314635-9A patent/BR0314635A/pt not_active Expired - Fee Related
- 2003-09-25 AR ARP030103499A patent/AR041395A1/es not_active Application Discontinuation
- 2003-09-25 WO PCT/EP2003/010930 patent/WO2004029026A1/en active IP Right Grant
- 2003-09-25 AT AT03750676T patent/ATE378317T1/de not_active IP Right Cessation
- 2003-09-25 EP EP03750676A patent/EP1565442B1/en not_active Expired - Lifetime
- 2003-09-25 MX MXPA05003263A patent/MXPA05003263A/es unknown
- 2003-09-25 NZ NZ538943A patent/NZ538943A/en unknown
- 2003-09-25 DE DE60317555T patent/DE60317555T2/de not_active Expired - Fee Related
- 2003-09-25 US US10/528,613 patent/US20060240048A1/en not_active Abandoned
- 2003-09-25 CN CNA038254727A patent/CN1703402A/zh active Pending
- 2003-09-25 AU AU2003268907A patent/AU2003268907A1/en not_active Abandoned
- 2003-09-25 ES ES03750676T patent/ES2294313T3/es not_active Expired - Lifetime
- 2003-09-25 CA CA002500231A patent/CA2500231A1/en not_active Abandoned
- 2003-09-25 RU RU2005112752/04A patent/RU2005112752A/ru not_active Application Discontinuation
-
2005
- 2005-03-11 ZA ZA200502084A patent/ZA200502084B/en unknown
- 2005-03-28 MA MA28176A patent/MA27448A1/fr unknown
- 2005-04-19 IS IS7809A patent/IS7809A/is unknown
- 2005-04-26 NO NO20052028A patent/NO20052028L/no not_active Application Discontinuation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2567390C2 (ru) * | 2009-08-24 | 2015-11-10 | Ньюралстем, Инк. | Получение нейростимулирующего пиперазина |
Also Published As
Publication number | Publication date |
---|---|
CN1703402A (zh) | 2005-11-30 |
NO20052028L (no) | 2005-06-03 |
MA27448A1 (fr) | 2005-07-01 |
WO2004029026A1 (en) | 2004-04-08 |
DE60317555T2 (de) | 2008-10-23 |
TW200413321A (en) | 2004-08-01 |
US20060240048A1 (en) | 2006-10-26 |
GB0222493D0 (en) | 2002-11-06 |
DE60317555D1 (de) | 2007-12-27 |
EP1565442B1 (en) | 2007-11-14 |
MXPA05003263A (es) | 2005-07-05 |
BR0314635A (pt) | 2005-08-02 |
AU2003268907A1 (en) | 2004-04-19 |
CA2500231A1 (en) | 2004-04-08 |
JP2006503845A (ja) | 2006-02-02 |
ATE378317T1 (de) | 2007-11-15 |
ZA200502084B (en) | 2006-02-22 |
ES2294313T3 (es) | 2008-04-01 |
IS7809A (is) | 2005-04-19 |
EP1565442A1 (en) | 2005-08-24 |
NZ538943A (en) | 2007-01-26 |
KR20050071514A (ko) | 2005-07-07 |
PL375990A1 (en) | 2005-12-12 |
AR041395A1 (es) | 2005-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2005112752A (ru) | Производные пиридина в качестве модуляторов рецептора сb2 | |
RU2375363C2 (ru) | Пирролотриазиновые производные анилина, полезные в качестве ингибиторов киназы | |
RU2353616C2 (ru) | Производные 2-пиридона в качестве ингибиторов эластазы нейтрофилов и их применение | |
CA2495880A1 (en) | Pyrimidine derivatives and their use as cb2 modulators | |
CA2540214A1 (en) | 2,4-dioxo-3-quinazolinylaryl sulfonylureas | |
HUP0002842A2 (hu) | Szubsztituált imidazolok, eljárás előállításukra, e vegyületeket tartalmazó gyógyászati készítmények, alkalmazásuk és intermedierjeik | |
EP0860428A3 (en) | Sulphonamide derivatives | |
HRP20110359T1 (hr) | Upotreba derivata 3-feniltio-1h-indol-1-octene kiseline kao modulatora crth2 receptorske aktivnosti | |
JP2006503845A5 (ru) | ||
RU2008125196A (ru) | Новые производные тиофена | |
WO2002094794A8 (en) | 4 (phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain anxiety or gastrointestinal disorders | |
WO2003024441A1 (fr) | Nouvelle utilisation de composes tricycliques | |
GB0224919D0 (en) | Triazole compounds useful in therapy | |
JP2007534755A5 (ru) | ||
MXPA04003056A (es) | Derivados de 4?piperidin-4-iliden-(3-carbamoilfenil)metil? benzamida y su uso para tratamiento de dolor, lesiones espinales o transtornos gastrointestinales. | |
CO5611136A2 (es) | Derivados de 4-(fenil-(piperidin-4-iliden-metil)-benzamida y su uso para el tratramiento del dolor, ansiedad o desordenes gastrointestinales | |
HUP0203976A2 (hu) | Adenozin a3 receptor antagonisták, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
JP2010513489A5 (ru) | ||
IL150126A0 (en) | Novel 4(piperazinyl(8-quinolinyl)methyl) benzamides | |
SE0101766D0 (sv) | Novel compounds | |
AR043273A1 (es) | Derivados de bifenilo, su uso, un proceso para prepararlos y medicamentos que los contienen. | |
ES449596A1 (es) | Procedimiento para la preparacion de nuevos derivados de pi-rimidina. | |
MXPA03010438A (es) | Derivados de 4-(fenil-piperidin-4-iliden-metil)-benzamida y su uso para tratar dolor, ansiedad o transtornos gastrointestinales. | |
KR940009186A (ko) | 이미다조피리딘 | |
BR0103180A (pt) | Derivados do diazabiciclooctano e suas utilizações terapêuticas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20080812 |